On March 13, 2019 Sanofi reported that it has successfully priced its offering of EUR 2 billion of notes (the "Notes") across 3 tranches (Press release, Sanofi, MAR 13, 2019, View Source [SID1234534266]):

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

€850 million fixed rate notes, due March 2022, bearing interest at an annual rate of 0.0%
€650 million fixed rate notes, due March 2029, bearing interest at an annual rate of 0.875%
€500 million fixed rate notes, due March 2034, bearing interest at an annual rate of 1.25%

The Notes are being issued off the company’s Euro Medium Term Note Programme.

The transaction enables the company to lower its average cost of debt and extend the average maturity of its debt.

Sanofi intends to use the net proceeds of the offering for general corporate purposes.

BofA – Merrill Lynch and Natixis acted as Global Coordinators and Bookrunners, alongside ING and Santander which acted as Bookrunners for the offering.